Clinical impact of genetic alterations including germline DDX41 mutations in MDS/low-blast count AML patients treated with azacitidine-based regimens.
Marie SébertLucie FreimanCendrine ChaffautAgnès GuerciPierre PeterlinSylvain ThépotOdile Beyne-RauzySophie ParkThomas CluzeauFatiha ChermatPierre FenauxClaude PreudhommeEmmanuelle ClappierSylvie ChevretLionel AdesNicolas DuployezMatthieu DuchmannPublished in: Leukemia (2024)